Maryland Bills Introduced to Bar 340B Contract Pharmacy Restrictions

Maryland state Sen. Clarence Lam (D) sponsored one of two bills introduced to prohibit drugmaker 340B contract pharmacy restrictions in the state.
Maryland lawmakers in the state house and senate have introduced companion bills that would prohibit drugmaker 340B contract pharmacy restrictions [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Hospital Groups Key 2024 Priorities Include Contract Pharmacy Protections Among Other 340B Goals

American Hospital Association seal on interior office wall
The American Hospital Association and other major hospital groups have placed multiple 340B program goals on their 2024 advocacy agendas.
Several national hospital groups name 340B contract pharmacy protections, among other 340B goals, in their 2024 advocacy priorities. The American [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Broad Stakeholder Support for Senate Group of Six Draft 340B Overhaul

The “Group of Six” is expected to announce this week that it plans to release the SUSTAIN Act by the end of the year.
Recently released draft congressional legislation to reform the 340B program has drawn positive initial reactions from across the range of [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

340B Lobbying Reaches Record Levels in 2023

Jackson Hammond of the American Action Forum said financial pressure was a driver of PhRMA's increased lobbying efforts.
Lobbying on 340B issues reached a record level in 2023, according to annual tallies of congressional lobbying disclosures. That flurry [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Federal Judge Rules for Diabetes Drugmakers in 340B Antitrust Case, Health Center Plans Appeal

Mosaic Health plans to appeal a federal district judge's ruling against the health center's 340B antitrust case against four diabetes drugmakers.
A federal district judge last week denied two community health centers’ antitrust claims against four major diabetes drug manufacturers over [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Mississippi Bill Introduced to Bar 340B Contract Pharmacy Restrictions, PBM Underpayments

Mississippi state Sen. Brice Wiggins (R) introduced one of two bills designed to protect 340B contract pharmacy use and bar PBM 340B underpayments in the state.
Eight Mississippi state senators have introduced a bill to bar drugmakers from restricting 340B contract pharmacy use and pharmacy benefit [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

GSK Posts 340B Refund Notice on High-Revenue Asthma Treatment

GlaxoSmithKline wordmark and GSK logo on a building
GlaxoSmithKline and Pfizer announced updates to their 340B contract pharmacy policies to comply with new state laws that will take effect in July.
Drugmaker GlaxoSmithKline has posted another refund notice to 340B providers related to purchases of its high-earning asthma drugs. A Jan. [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Breaking News

Highly Anticipated Draft 340B Bill Released by Bipartisan Senate Gang of Six

The “Group of Six” is expected to announce this week that it plans to release the SUSTAIN Act by the end of the year.
After more than six months of long meetings with stakeholders, a bipartisan group of six senators released draft legislation Friday [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Genesis Ruling Creates Legal, Regulatory Uncertainty for 340B, Says Attorney Panel

Maureen Testoni, president and CEO of 340B Health, Jason Reddish, a principal at Powers Law, and Ross Margulies, a partner at Foley Hoag, discussed the looming uncertainty in 340B following a key federal district court ruling during the 340B Coalition Winter Conference.
A recent federal district court ruling on the 340B patient definition created a “gray area” for 340B providers and drugmakers, [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Potential Senate Flip May Increase 340B Scrutiny, But Congressional 340B Action Unlikely in 2024, Say 340B Advocate, Drug Industry Analyst

Michael McCaughan, co-founder of Provision Policy, spoke about drug pricing policy at the 340B Coalition Winter Conference.
Congress is unlikely to act on 340B in 2024, but a potential flip of the U.S. Senate could lead to [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live